New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
08:39 EDTCMRXChimerix shares remain undervalued, says Cowen
Cowen believes shares of Chimerix remain undervalued following its dinner management. The firm remains confident its SUPPRESS trial for brincidofovir will succeed in 2015 and expects other opportunities for the drug to materialize in 2014. Shares are Outperform rated with a $27 price target.
News For CMRX From The Last 14 Days
Check below for free stories on CMRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CMRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use